Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature
Characterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. Gorham’s lymphangiomatosis or Gorham–Stout disease (GSD) is a rare skeletal condition of unknown etiology characte...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2022/8331766 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563442408488960 |
|---|---|
| author | Matthew Lee Beth A. Martin Haifaa Abdulhaq |
| author_facet | Matthew Lee Beth A. Martin Haifaa Abdulhaq |
| author_sort | Matthew Lee |
| collection | DOAJ |
| description | Characterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. Gorham’s lymphangiomatosis or Gorham–Stout disease (GSD) is a rare skeletal condition of unknown etiology characterized by progressive bone loss and nonmalignant proliferation of vascular and lymphatic channels within the affected bone. Neither disease has a standard of care. We present a 23-year-old HIV-negative woman with GSD, managed medically with octreotide and sirolimus, who developed PBL. After progressing on V-EPOCH (bortezomib, etoposide, vincristine, cyclophosphamide, doxorubicin, and prednisone), she was treated with daratumumab, lenalidomide, and dexamethasone (DRD) therapy and achieved complete remission after two cycles with progression after eight cycles. This is a report of treatment of PBL with DRD therapy. Clinical investigations of the DRD regimen in PBL in conjunction with other agents to improve both depth and durability of response are warranted. |
| format | Article |
| id | doaj-art-868e3d9247fa4004beb4ce2bc7e61adc |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-868e3d9247fa4004beb4ce2bc7e61adc2025-02-03T01:20:08ZengWileyCase Reports in Hematology2090-65792022-01-01202210.1155/2022/8331766Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the LiteratureMatthew Lee0Beth A. Martin1Haifaa Abdulhaq2UCSF FresnoStanford UniversityUCSF FresnoCharacterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. Gorham’s lymphangiomatosis or Gorham–Stout disease (GSD) is a rare skeletal condition of unknown etiology characterized by progressive bone loss and nonmalignant proliferation of vascular and lymphatic channels within the affected bone. Neither disease has a standard of care. We present a 23-year-old HIV-negative woman with GSD, managed medically with octreotide and sirolimus, who developed PBL. After progressing on V-EPOCH (bortezomib, etoposide, vincristine, cyclophosphamide, doxorubicin, and prednisone), she was treated with daratumumab, lenalidomide, and dexamethasone (DRD) therapy and achieved complete remission after two cycles with progression after eight cycles. This is a report of treatment of PBL with DRD therapy. Clinical investigations of the DRD regimen in PBL in conjunction with other agents to improve both depth and durability of response are warranted.http://dx.doi.org/10.1155/2022/8331766 |
| spellingShingle | Matthew Lee Beth A. Martin Haifaa Abdulhaq Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature Case Reports in Hematology |
| title | Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature |
| title_full | Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature |
| title_fullStr | Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature |
| title_full_unstemmed | Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature |
| title_short | Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature |
| title_sort | daratumumab lenalidomide and dexamethasone drd an active regimen in the treatment of immunosuppression associated plasmablastic lymphoma pbl in the setting of gorham s lymphangiomatosis review of the literature |
| url | http://dx.doi.org/10.1155/2022/8331766 |
| work_keys_str_mv | AT matthewlee daratumumablenalidomideanddexamethasonedrdanactiveregimeninthetreatmentofimmunosuppressionassociatedplasmablasticlymphomapblinthesettingofgorhamslymphangiomatosisreviewoftheliterature AT bethamartin daratumumablenalidomideanddexamethasonedrdanactiveregimeninthetreatmentofimmunosuppressionassociatedplasmablasticlymphomapblinthesettingofgorhamslymphangiomatosisreviewoftheliterature AT haifaaabdulhaq daratumumablenalidomideanddexamethasonedrdanactiveregimeninthetreatmentofimmunosuppressionassociatedplasmablasticlymphomapblinthesettingofgorhamslymphangiomatosisreviewoftheliterature |